Molecular Imaging

分子成像

基本信息

批准号：
8300273
负责人：
MAX S. WICHA
金额：
$ 4.96万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-06-01 至 2017-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8300273
关键词：
Algorithms Animal Model Animals Antineoplastic Protocols Area Autoradiography Award Binding Biological Biological Markers Biology Bone Lymphoma Brain Breast CXCR Caliber Cancer Center Support Grant Cancer Diagnostics Cancer Etiology Cancer Patient Cell Surface Receptors Cells Clinic Clinical Clinical Drug Development Clinical Research Clinical Trials Collaborations Combined Modality Therapy Contracts Contrast Media Data Data Set Detection Development Diagnosis Diffusion Diffusion Magnetic Resonance Imaging Disease Doctor of Philosophy Dose Drug Delivery Systems Early Diagnosis Early treatment Enhancing Lesion Epidermal Growth Factor Receptor Evaluation Fiber Optics Fluorescence Focus Groups Fostering Functional disorder Funding Gastrointestinal tract structure Glioma Goals Grant Head and Neck Cancer Head and neck structure Hematologic Neoplasms Histology Human Image Image Analysis Imaging Device Imaging Techniques Imaging technology Individual Intensity-Modulated Radiotherapy Investigation Ionizing radiation Label Laboratory Study Lesion Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of liver Malignant neoplasm of pancreas Malignant neoplasm of prostate Maps Measures Medical Metastatic Prostate Cancer Metastatic to Methodology Methods Metric Michigan Mission Modality Modeling Molecular Monitor Motion Mucous Membrane Multi-Institutional Clinical Trial Neoadjuvant Therapy Nuclear Oncogenic Optics Organ Outcome Patient Care Patients Peptides Performance Perfusion Phase Physiological Pilot Projects Play Positron-Emission Tomography Preclinical Drug Development Premalignant Process Program Research Project Grants Property Prostate Proteins Protocols documentation Protons Publications Quality Control Radiation Reagent Reporter Research Research Infrastructure Research Personnel Research Support Resources Risk Schedule Science Scientist Screening for cancer Screening procedure Shipping Ships Signal Pathway Signal Transduction Signaling Molecule Southwest Oncology Group Spectrum Analysis Staging System Techniques Technology Temperature Therapeutic Time Tissues Tracer Training Translating Translational Research Translations Treatment Efficacy Treatment outcome Ultrasonography United States National Institutes of Health Universities University of Michigan Comprehensive Cancer Center Unresectable Validation Water Work anticancer research base bone cancer diagnosis cancer imaging cancer stem cell cancer therapy career development chemotherapy clinical application cohort cytotoxic digital imaging dosage driving force drug development gemcitabine hemodynamics image processing image registration imaging Segmentation imaging probe improved in vivo in vivo Cellular and Molecular Imaging Centers insight instrument instrumentation irradiation large cell Diffuse non-Hodgkin&apos s lymphoma malignant breast neoplasm meetings member molecular imaging multidisciplinary multimodality neoplastic new technology novel oncology oncology program optical imaging pre-clinical preclinical evaluation programs prospective research study response sarcoma single photon emission computed tomography standard of care stem cell population success technology development tool treatment response tumor

项目摘要

The Molecular Imaging Program (MIP) consists of 19 members from 7 different departments. Since the last funding cycle the research base of the Program increased 46% from $5,740,595 total annual direct research support, of which $6,393,909 Is from the NCI. Over this last grant period, there were 188 publications of the Molecular Imaging Program, of which 28,7% were intra-programmatic and 36,7% were inter-programmatic. The program has made significant advances in developing novel technologies that facilitate diagnosis and treatment of cancer, and also has provided methodologies and reagents wherein the efficacy of various therapeutics can be monitored in real-time in pre-clinical and clinical settings. These advances include the development of novel molecular Imaging reporter molecules which have Improved our understanding of cancer etiology, biology, pathophysiology and therapy. We will continue to develop cutting edge approaches for imaging the presence of pre-malignant (dysplastic) tissue and oncogenic signaling molecules in vivo. We have developed an Integrated optical molecular Imaging strategy that uses fluorescence peptides as probes to target the presence of pre-malignant (dysplastic) tissue in vivo. The recruitment of Thomas Wang MD, PhD from Stanford University provides the MIP with new capabilities, especially the development of novel optical Imaging probes and instrumentation that can be used as a diagnostic cancer screen for early detection in variousorgans. Drs Ross, Rehemtulla and Luker will continue to develop and validate molecular imaging reporters (i.e. CXCR, c-Met and Akt), Non-invasive imaging in cells and animals will be used to evaluate these novel reporter constructs for detection of key oncogenic signaling pathways. These tools and concepts should significantly aid in our preclinical drug development process and provide insights into more efficacious combination therapy strategies for tumors. Drs Ross, Meyer and Chenevert will continue to develop novel MR-imaging based surrogates for quantification of early therapeutic efficacy in cancer patients. Recent breakthroughs in this area include the concept that analysis of changes within individual voxels (parametric response mapping, PRM) over time, provide a much more robust and predictive quantitative measure of treatment response than current approaches. Application of the PRM concept to clinical trials in brain, breast, head and neck as well as in prostate cancer metastatic to bone, have yielded results that demonstrate the early predictive power of MR-imaging especially when combined with PRM analysis.

分子成像程序（MIP）由来自7个不同部门的19个成员组成。自上次筹资周期以来，该计划的研究基础从5,740,595美元的年度直接研究支持增加了46％，其中6,393,909美元来自NCI。在最后一个赠款期间，有188个分子成像程序出版物，其中28,7％是概括性的，36.7％是策略室间的。该计划在开发促进癌症诊断和治疗的新技术方面取得了重大进步，并提供了方法和试剂，在这些方法和试剂中，可以在临床前和临床环境中实时监测各种治疗剂的功效。这些进步包括开发新的分子成像报告基因分子，这些分子已经提高了我们对癌症病因，生物学，病理生理学和治疗的理解。我们将继续开发尖端方法，以成像体内的恶性（异型）组织和致癌信号分子的存在。我们已经开发了一种综合的光学分子成像策略，该策略使用荧光肽作为探针，以靶向体内的恶性（异型酶）组织的存在。来自斯坦福大学的Thomas Wang MD博士的招募提供了具有新功能的MIP，尤其是开发新型的光学成像探针和仪器，可以用作各种魔法师早期检测的诊断癌症筛查。 Ross Dr Ross，Rehemtulla和Luker将继续开发和验证分子成像报告基因（即CXCR，C-MET和AKT），细胞和动物中的非侵入性成像将用于评估这些新型记者构建体以检测关键的癌症信号通路的关键构造。这些工具和概念应大大有助于我们的临床前药物开发过程，并提供对肿瘤更有效的组合疗法策略的见解。罗斯博士，迈耶和切纳弗特将继续发展基于MR成像的新型替代物，以定量癌症患者的早期治疗功效。该领域的最新突破包括一个概念，即随着时间的推移，分析单个体素（参数响应映射，PRM）内的变化，提供了比当前方法更强大和预测的治疗响应定量度量。 PRM概念在大脑，乳腺癌，头颈以及前列腺癌转移到骨骼中的临床试验中的应用，产生了结果，证明了MR成像的早期预测能力，尤其是与PRM分析结合在一起时。